Drug Discovery

Twist Bioscience, Artisan Development Labs partner to discover cell therapies

Twist Bioscience has teamed up with Artisan Development Labs to discover new antibodies against five undisclosed targets.

Prellis, Bristol Myers Squibb collaborate to discover antibodies

Prellis Biologics and Bristol Myers Squibb have signed a multi-target collaboration and license agreement to discover antibodies.

Lantern Pharma and NCI expand oncology partnership

Lantern Pharma and the US National Institutes of Health unit National Cancer Institute’s (NCI) Developmental Therapeutics Branch (DTB) have announced the extension of their oncology collaboration for first in human clinical trials for drug candidates LP-184 and LP-284.

Absci and Merck collaborate to develop new enzymes

Drug and target discovery company Absci has signed a research collaboration with Merck to produce new enzymes.

Amgen, Generate Biomedicines partner to create protein therapeutics

Amgen has entered into a research collaboration agreement with Generate Biomedicines to discover and create protein therapeutics for five clinical targets across several modalities.

Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline

Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.

Ascletis expands ritonavir oral tablets production amid Covid-19 surge

Ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.

AstraZeneca, Ionis close deal on antisense therapy development

Under the deal, AstraZeneca will manage the development and marketing of the antisense therapy globally.

BSF Enterprise to acquire 3D Bio-Tissues

BSF Enterprise has signed a conditional agreement to acquire 3D Bio-Tissues (3DBT) in a deal worth $3.34m (£2.5m).